Guinea vs Syrian Arab Republic: Average cost of drugs for extensively drug-resistant tuberculosis
Guinea
5,356 constant 2022 US$
in 2024
Syrian Arab Republic
5,125 constant 2022 US$
in 2023
Guinea rank
9th
Syrian Arab Republic rank
10th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Guinea
- Syrian Arab Republic
How they compare
Guinea currently reports 5,356 constant 2022 US$ against 5,125 constant 2022 US$ in Syrian Arab Republic, a difference of 231 constant 2022 US$.
Across all 7 years both countries report, Guinea has been ahead every year.
Guinea ranks 9th and Syrian Arab Republic ranks 10th of 56 countries.
Guinea has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guinea | Syrian Arab Republic | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 8,964 constant 2022 US$ | 6,000 constant 2022 US$ | 2,964 constant 2022 US$ | Guinea |
| 2020s | 8,736 constant 2022 US$ | 5,781 constant 2022 US$ | 2,955 constant 2022 US$ | Guinea |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Guinea or Syrian Arab Republic?
- Guinea, at 5,356 constant 2022 US$ against 5,125 constant 2022 US$ in Syrian Arab Republic as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Guinea and Syrian Arab Republic?
- 231 constant 2022 US$, with Guinea ahead.
- How many years of comparable data are there for Guinea and Syrian Arab Republic?
- 7 years are reported by both, from 2017 to 2023.
- How do Guinea and Syrian Arab Republic rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Guinea ranks 9th and Syrian Arab Republic ranks 10th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.